We examine potential sources of unfairness in clinical trials, addressing ML from several angles: the potential for ML to improve patient welfare and equity, the risks of propagating unfairness, and its potential to facilitate the use of emergent adaptive designs.
We also curate a list of opportunities for innovation in ML to address these sources of unfairness, providing and overview of relevant current literature and highlighting critical future directions.